Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vibrio cholerae Inaba 48 classical biotype, heat inactivated
- Development stage
- Unknown
- Lead developer
- Valneva
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
Vibrio cholerae Inaba 48 classical biotype, heat inactivated is a component of oral killed whole-cell vaccines used for the prevention of cholera. It consists of Vibrio cholerae O1 Inaba serogroup bacteria (classical biotype) that have been rendered non-infectious by heat treatment. This strain is included as an antigenic component to stimulate immunity against V. cholerae O1 Inaba strains responsible for epidemic and pandemic cholera. The mechanism of action involves induction of mucosal and systemic immune responses against V. cholerae antigens, thereby providing protection from infection and severe diarrheal disease caused by this pathogen[6][8]. It is commonly formulated with other V. cholerae strains (Ogawa/Inaba; El Tor/classical) and sometimes recombinant B subunit of the toxin as part of multivalent oral vaccines such as Dukoral[6]. The primary indication is prophylaxis against infection with Vibrio cholerae O1.
- Brand names
- dukoral
- Other names
- vibrio cholerae o1 inaba classical biotype heat inactivatedvibrio cholerae o1 inaba cairo 48 classical biotype heat inactivated
02
Targets
Vibrio cholerae O1 El Tor Inaba
Beyond the preview
Go deeper on Vibrio cholerae Inaba 48 classical biotype, heat inactivated.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vibrio cholerae Inaba 48 classical biotype, heat inactivated.